We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Phase II trial of a treatment designed to repair heart muscle in patients with heart failure has been placed on clinical hold at the FDA’s direction after a patient suffered a serious adverse event (SAE) related to “anesthesia management,” Aastrom Biosciences says.